Hubbry Logo
ParvoviridaeParvoviridaeMain
Open search
Parvoviridae
Community hub
Parvoviridae
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Parvoviridae
Parvoviridae
Parvoviridae
View on Wikipedia
from Wikipedia
"Parvo", "parvovirus", and "parvo virus" redirect here. For the dog disease, see canine parvovirus. For the cat disease, see feline parvovirus. For the pig disease, see porcine parvovirus. For the human disease caused by parvovirus B19, see fifth disease.

Parvoviridae
Electron micrograph of canine parvovirus
Electron micrograph of canine parvovirus
Virus classification Edit this classification
(unranked): Virus
Realm: Monodnaviria
Kingdom: Shotokuvirae
Phylum: Cossaviricota
Class: Quintoviricetes
Order: Piccovirales
Family: Parvoviridae
Genera

See text

Parvoviruses are a family of animal viruses that constitute the family Parvoviridae. They have linear, single-stranded DNA (ssDNA) genomes that typically contain two genes encoding for a replication initiator protein, called NS1, and the protein the viral capsid is made of. The coding portion of the genome is flanked by telomeres at each end that form into hairpin loops that are important during replication. Parvovirus virions are small compared to most viruses, at 23–28 nanometers in diameter, and contain the genome enclosed in an icosahedral capsid that has a rugged surface.

Parvoviruses enter a host cell by endocytosis, travelling to the nucleus where they wait until the cell enters its replication stage. At that point, the genome is uncoated and the coding portion is replicated. Viral messenger RNA (mRNA) is then transcribed and translated, resulting in NS1 initiating replication. During replication, the hairpins repeatedly unfold, are replicated, and refold to change the direction of replication to progress back and forth along the genome in a process called rolling hairpin replication that produces a molecule containing numerous copies of the genome. Progeny ssDNA genomes are excised from this concatemer and packaged into capsids. Mature virions leave the cell by exocytosis or lysis.

Parvoviruses are believed to be descended from ssDNA viruses that have circular genomes that form a loop because these viruses encode a replication initiator protein that is related to NS1 and have a similar replication mechanism. Another group of viruses called bidnaviruses appear to be descended from parvoviruses. Within the family, three subfamilies and 28 genera are recognized. Parvoviridae is the sole family in the order Piccovirales, which is the sole order in the class Quintoviricetes. This class is assigned to the phylum Cossaviricota, which also includes papillomaviruses, polyomaviruses, and bidnaviruses.

A variety of diseases in animals are caused by parvoviruses. Notably, the canine parvovirus and feline parvovirus cause severe disease in dogs and cats, respectively. In pigs, the porcine parvovirus is a major cause of infertility. Human parvoviruses are less severe, the two most notable being parvovirus B19, which causes a variety of illnesses including fifth disease in children, and human bocavirus 1, which is a common cause of acute respiratory tract illness, especially in young children. In medicine, recombinant adeno-associated viruses (AAV) have become an important vector for delivering genes to the cell nucleus during gene therapy.

Animal parvoviruses were first discovered in the 1960s, including minute virus of mice, which is frequently used to study parvovirus replication. Many AAVs were also discovered during this time period and research on them over time has revealed their benefit as a form of medicine. The first pathogenic human parvovirus to be discovered was parvovirus B19 in 1974, which became associated with various diseases throughout the 1980s. Parvoviruses were first classified as the genus Parvovirus in 1971 but were elevated to family status in 1975. They take their name from the Latin word parvum, meaning 'small' or 'tiny', referring to the small size of the virus's virions.

Genome

[edit]

Parvoviruses have linear, single-stranded DNA (ssDNA) genomes that are about 4–6 kilobases (kb) in length. The parvovirus genome typically contains two genes, termed the NS/rep gene and the VP/cap gene.[1] The NS gene encodes the non-structural (NS) protein NS1, which is the replication initiator protein, and the VP gene encodes the viral protein (VP) that the viral capsid is made of. NS1 contains an HUH superfamily endonuclease domain near its N-terminus, containing both site-specific binding activity and site-specific nicking activity, and a superfamily 3 (SF3) helicase domain toward the C-terminus. Most parvoviruses contain a transcriptional activation domain near the C-terminus that upregulates transcription from viral promoters as well as alternate or overlapping open reading frames that encode a small number of supporting proteins involved in different aspects of the viral life cycle.[2]

The coding portion of the genome is flanked at each end by terminal sequences about 116–550 nucleotides (nt) in length that consist of imperfect palindromes folded into hairpin loop structures. These hairpin loops contain most of the cis-acting information required for DNA replication and packaging and act as hinges during replication to change the direction of replication. When the genome is converted to double-stranded forms, replication origin sites are created involving sequences in and adjacent to the hairpins.[2][3]

Genomic DNA strands in mature virions may be positive-sense or negative-sense. This varies from species to species as some have a preference for packaging strands of one polarity, others package varying proportions, and others package both sense strands at equal proportions. These preferences reflect the efficiency with which progeny strands are synthesized, which in turn reflects the efficiency of specific replication origin sites.[2] The 3′-end (usually pronounced "three prime end") of a negative sense strand, and the 5′-end (usually pronounced "five prime end") of a positive sense strand, is called the left end, and the 5′-end of the negative sense strand, and the 3′-end of a positive sense strand, is called the right end.[2][4][5]

Structure

[edit]
Schematic diagram of a Parvoviridae virion
A diagram of the canine parvovirus's capsid, containing 60 monomers of the capsid protein.

Parvovirus virions are 23–28 nanometers (nm) in diameter and consist of the genome enclosed inside a capsid that is icosahedral in shape with a rugged surface. The capsid is composed of 60 structurally equivalent polypeptide chains derived from the C-terminal end of a VP protein's sequence, interlocking extensively to form an icosahedron with 60 asymmetric, superficial triangular units. These units have 3-fold radial symmetry at two vertices and 5-fold radial symmetry at one, with 2-fold radial symmetry at the line opposite of the 5-fold vertex and a 2/5 circular fold wall surrounding the point of the 5-fold vertex. Twenty 3-fold vertices, thirty 2-fold lines, and twelve 5-fold vertices exist per capsid, the latter corresponding to the 12 vertices of the icosahedron.[2]

Typical features of the capsid surface include depressions at each 2-fold axis, elevated protrusions surrounding the 3-fold axes, and raised cylindrical projections made of five beta-barrels[6] surrounded by canyon-like depressions at the 5-fold axes. Each of these cylinders potentially contains an opening to connect the exterior of the capsid to the interior, which mediates entry and exit of the genome. About 20 nucleotides from the 5′-end of the genome may remain exposed outside of the capsid carrying a copy of NS1 bound to the 5′-end, which is a result of how the genome is synthesized and packaged.[2]

Varying sizes of the VP protein are expressed for different parvoviruses, the smaller ones, VP2–5, being expressed at a higher frequency than the large size, VP1. The smaller VPs share a common C-terminus with different N-terminus lengths due to truncation. For VP1, the N-terminus is extended to contain regions important in the replication cycle, and it is incorporated into the capsid, typically 5–10 per capsid, with the common C-terminus responsible for assembling capsids.[1][2]

Each VP monomer contains a core beta-barrel structure called the jelly roll motif of eight strands arranged in two adjacent antiparallel beta sheets, labeled CHEF and BIDG after the individual strands, the latter forming the interior surface of the capsid. Individual beta strands are connected by loops that have varying length, sequence, and conformation, and most of these loops extend toward the exterior surface, giving parvoviruses their unique, rough surface. Related parvoviruses share their surface topologies and VP protein folds to a greater degree than their sequence identities, so the structure of the capsid and capsid protein are useful indicators of phylogeny.[1][2]

Life cycle

[edit]

Parvoviruses enter cells by endocytosis, using a variety of cellular receptors to bind to the host cell. In endosomes, many parvoviruses undergo a change in conformation so that the phospholipase A2 (PLA2) domain on the VP1 N-termini are exposed so the virion can penetrate lipid bilayer membranes. Intracellular trafficking of virions varies, but virions ultimately arrive to the nucleus, inside of which the genome is uncoated from the capsid. Based on studies of minute virus of mice (MVM), the genome is ejected from the capsid in a 3′-to-5′ direction from one of the openings in the capsid, leaving the 5′-end of the DNA attached to the capsid.[2]

Parvoviruses lack the ability to induce cells into their DNA replication stage, called S-phase, so they must wait in the nucleus until the host cell enters S-phase on its own. This makes cell populations that divide rapidly, such as fetal cells, an excellent environment for parvoviruses. Adeno-associated viruses (AAV) are dependent on helper viruses, which may be an adenovirus or a herpesvirus, since coinfection alters the cellular environment to allow for replication.[2] In the absence of coinfection, AAV's genome is integrated into the host cell's genome until coinfection occurs.[7] Infected cells that enter S-phase are forced to synthesize viral DNA and cannot leave S-phase. Parvoviruses establish replication foci in the nucleus that grow progressively larger as infection progresses.[8]

Once a cell enters S-phase and the genome is uncoated, a host DNA polymerase uses the 3′-end of the 3′ hairpin as a primer to synthesize a complementary DNA strand for the coding portion of the genome, which is connected to the 5′-end of the 5′ hairpin.[3][7][9] Messenger RNA (mRNA) that encodes NS1 is then transcribed from the genome by the DNA polymerase, capped and polyadenylated, and translated by host ribosomes to synthesize NS1.[2][5][10] If proteins are encoded in multiple co-linear frames, then alternative splicing, suboptimal translation initiation, or leaky scanning may be used to translate different gene products.[2]

Parvoviruses replicate their genome via rolling hairpin replication, a unidirectional, strand displacement form of DNA replication that is initiated by NS1. Replication begins once NS1 binds to and makes a nick in a replication origin site in the duplex DNA molecule at the end of one hairpin. Nicking releases the 3′-end of the nicked strand as a free hydroxyl (-OH) to prime DNA synthesis[2] with NS1 remaining attached to the 5′-end.[7] The nick causes the adjacent hairpin to unfold into a linear, extended form. At the 3′-OH, a replication fork is established using NS1's helicase activity, and the extended telomere is replicated by the DNA polymerase.[10][11] The two telomere strands then refold back in on themselves to their original configurations, which repositions the replication fork to switch templates to the other strand and move in the opposite direction toward the other end of the genome.[12][13]

Parvoviruses vary in whether the termini are similar or the same, called homotelomeric parvoviruses, or different, called heterotelomeric parvoviruses. In general, homotelomeric parvoviruses, such as AAV and B19, replicate both ends of their genome through the aforementioned process, called terminal resolution, and their hairpin sequences are contained within larger (inverted) terminal repeats. Heterotelomeric viruses, such as minute virus of mice (MVM), replicate one end by terminal resolution and the other end via an asymmetric process called junction resolution[2][14] so that the correct orientation of the telomere can be copied.[15]

During asymmetric junction resolution, the duplex extended-form telomeres refold in on themselves into a cruciform shape. A replication origin site on the lower strand of the right arm of the cruciform is nicked by NS1, leading to the lower arm of the cruciform unfolding into its linear extended form. A replication fork established at the nick site moves down the extended lower arm to copy the lower arm's sequence. The two strands of the lower arm then refold to reposition the replication fork to go back toward the other end, displacing the upper strand in the process.[16]

The back and forth, end-to-end pattern of rolling hairpin replication produces a concatemer containing multiple copies of the genome.[2][3] NS1 periodically makes nicks in this molecule and, through a combination of terminal resolution and junction resolution, individual strands of the genome are excised from the concatemer.[9][13] Excised genomes may either be recycled for further rounds of replication or packaged into progeny capsids.[7] Translation of mRNA containing VP proteins leads to the accumulation of capsid proteins in the nucleus that assemble into these empty capsids.[8]

Genomes are encapsidated at one of the capsid's vertices through a portal,[2] potentially the one opposite the portal used to expel the genome.[5] Once complete virions have been constructed, they may be exported from the nucleus to the exterior of the cell before disintegration of the nucleus. Disruption of the host cell environment may also occur later on in the infection. This results in cell lysis via necrosis or apoptosis, which releases virions to the outside of the cell.[2][8]

Evolution

[edit]

Parvoviruses are believed to be descended from ssDNA viruses that have a circular genome that forms a loop and which replicate via rolling circle replication, which is similar to rolling hairpin replication. These circular ssDNA viruses encode a replication initiator protein that is related to and possesses many of the same characteristics as the replication initiator protein of parvoviruses, such as the HUH endonuclease domain and the SF3 helicase domain.[17] In contrast to these other replication initiator proteins, NS1 shows only vestigial traces of being able to perform ligation, which is a key part of rolling circle replication.[8] The Bidnaviridae family, which are also linear ssDNA viruses, appear to be descended from a parvovirus that had its genome integrated into the genome of a polinton, a type of DNA transposon related to viruses in the realm Varidnaviria.[17]

Based on phylogenetic analysis of the SF3 helicase, parvoviruses split into two branches early in their evolutionary history, one of which contains viruses assigned to the subfamily Hamaparvovirinae. The other branch split into two sublineages that constitute the other two subfamilies, Densovirinae and Parvovirinae.[18] Parvoviruses in the Hamaparvovirinae lineage are likely all heterotelomeric, Densovirinae are exclusively homotelomeric, and Parvovirinae varies.[2] Telomere sequences have significant complexity and diversity, suggesting that many species have co-opted them to perform additional functions.[7][10] Parvoviruses are also considered to have high rates of genetic mutations and recombinations.[2][9]

Classification

[edit]

Parvoviruses constitute the family Parvoviridae. The family is the sole family in the order Piccovirales, which is the sole order in the class Quintoviricetes. The class Quintoviricetes belongs to the phylum Cossaviricota, which also includes papillomaviruses, polyomaviruses, and bidnaviruses. Cossaviricota is included in the kingdom Shotokuvirae, which is assigned to the realm Monodnaviria. Parvoviridae belongs to Group II: ssDNA viruses in the Baltimore classification system, which groups viruses together based on their manner of mRNA synthesis. Within Parvoviridae, three subfamilies, 26 genera, and 126 species are recognized as of 2020 (-virinae denotes subfamily and -virus denotes genus):[18][19]

Aquambidensovirus
Blattambidensovirus
Diciambidensovirus
Hemiambidensovirus
Iteradensovirus
Miniambidensovirus
Muscodensovirus
Pefuambidensovirus
Protoambidensovirus
Scindoambidensovirus
Tetuambidensovirus
Brevihamaparvovirus
Chaphamaparvovirus
Hepanhamaparvovirus
Ichthamaparvovirus
Penstylhamaparvovirus
Amdoparvovirus
Artiparvovirus
Aveparvovirus
Bocaparvovirus
Copiparvovirus
Dependoparvovirus
Erythroparvovirus
Loriparvovirus
Protoparvovirus
Sandeparvovirus
Tetraparvovirus

Additionally, the family contains one genus unassigned to a subfamily: Metalloincertoparvovirus.[19]

Parvoviruses are assigned to the same species if they share at least 85% of their protein sequence identities. Species are grouped together in a genus based on phylogeny of the NS1 and SF3 helicase domains, as well as similarity of NS1 sequence identity and coverage. If these criteria aren't satisfied, then genera can still be established provided that common ancestry is supported. The three subfamilies are distinguished based on phylogeny of the SF3 helicase domain, which corresponds to host range: viruses in Densovirinae infect invertebrates, viruses in Hamaparvovirinae infect invertebrates and vertebrates, and viruses in Parvovirinae infect vertebrates.[18]

Disease

[edit]
Child with Fifth disease

In humans, the most prominent parvoviruses that cause disease are parvovirus B19 and human bocavirus 1. B19 infection is often asymptomatic but can manifest in a variety of ways, including Fifth disease with its characteristic rash in children, persistent anemia in immunocompromised persons and in people who have underlying hemoglobinopathies,[20] transient aplastic crises, hydrops fetalis in pregnant women, and arthropathy. Human bocavirus 1 is a common cause of acute respiratory tract infection, especially in young children, wheezing being a common symptom. Other parvoviruses associated with different diseases in humans include human parvovirus 4 and human bufavirus, though the manner by which these viruses cause disease is unclear.[6]

Carnivore-infecting viruses in the genus Protoparvovirus, in contrast to human parvoviruses, are more life-threatening.[2] Canine parvovirus causes severe illness in dogs, the most common symptom being hemorrhagic enteritis, with up to a 70% mortality rate in pups but usually less than 1% in adults.[21] Feline parvovirus, a closely related virus,[22] likewise causes severe illness in cats along with panleukopenia.[23][24] In pigs, porcine parvovirus is a major cause of infertility as infection frequently leads to death of the fetus.[25]

Use in medicine

[edit]

Adeno-associated viruses have become an important vector for gene therapy aimed at treating genetic diseases, such as those caused by a single mutation. The recombinant AAV (rAAV) contains a viral capsid but lacks a complete viral genome. Instead, the typical nucleic acid packaged into the capsid contains a promoter region, the gene of interest, and a terminator region, all contained within two inverted terminal repeats derived from the viral genome. rAAV essentially acts as a container that can traverse the cell membrane and deliver its nucleic acid cargo to the nucleus.[26][27]

History

[edit]

Parvoviruses were discovered relatively late in comparison to other prominent virus families, potentially due to their small size. In the late 1950s[28] and 1960s,[29] a variety of animal parvoviruses were discovered, including minute virus of mice,[30] which has since been used extensively to study rolling hairpin replication.[31] Many AAVs were also discovered during this time period[32] and research on them led to their first usage in gene therapy in the 1980s. Over time, improvements in aspects such as vector design led to certain AAV gene therapy products reaching clinical efficacy in 2008 and being approved in the following years.[27]

In 1974, the first pathogenic human parvovirus was discovered by Tamim.k, N.I Urbi, et al. When testing for the hepatitis B virus's surface antigen, one serum sample gave anomalous results and with electron microscopy was shown to contain a virus resembling animal parvoviruses. This virus was named B19 after the coding of the serum sample, number 19 in panel B.[20][33] B19 was later recognized as a species by the International Committee on Taxonomy of Viruses (ICTV) in 1985, and throughout the 1980s it increasingly became associated with various diseases.[33]

In the ICTV's first report in 1971, parvoviruses were grouped together in the genus Parvovirus.[30][32] They were elevated to the rank of family in 1975 and remained unassigned to higher taxa until 2019, when they were assigned to higher taxa up to the highest rank, realm.[34] The family was reorganized in 2019, departing from the "traditional" invertebrate-vertebrate distinction between Densovirinae and Parvovirinae and instead distinguishing the subfamilies based on helicase phylogeny, leading to the establishment of a new subfamily, Hamaparvovirinae.[18]

Etymology

[edit]

Parvoviruses take their name from Latin parvus or parvum, meaning small or tiny, referring to the small size of parvovirus virions compared to most other viruses.[2][20] In the family name Parvoviridae, -viridae is the suffix used for virus families.[35] The order Piccovirales takes the first part of its name from the Italian word piccolo, meaning small, and the second part is the suffix used for virus orders. The class Quintoviricetes takes the first part of its name from the Galician word quinto, meaning fifth, referring to fifth disease (erythema infectiosum) caused by parvovirus B19, and viricetes, the suffix used for virus classes.[17]

See also

[edit]

Citations

[edit]
  1. ^ a b c Mietzsch M, Pénzes JJ, Agbandje-McKenna M (20 April 2019). "Twenty-Five Years of Structural Parvovirology". Viruses. 11 (4): 362. doi:10.3390/v11040362. PMC 6521121. PMID 31010002.
  2. ^ a b c d e f g h i j k l m n o p q r s t u Cotmore SF, Agbandje-McKenna M, Canuti M, Chiorini JA, Eis-Hubinger AM, Hughes J, Mietzsch M, Modha S, Ogliastro M, Pénzes JJ, Pintel DJ, Qiu J, Soderlund-Venermo M, Tattersall P, Tijssen P (March 2019). "ICTV Virus Taxonomy Profile: Parvoviridae". J Gen Virol. 100 (3): 367–368. doi:10.1099/jgv.0.001212. PMC 6537627. PMID 30672729. Retrieved 24 January 2021.
  3. ^ a b c Kerr, Cotmore & Bloom 2005, p. 177.
  4. ^ Kerr, Cotmore & Bloom 2005, p. 172.
  5. ^ a b c Cotmore SF, Tattersall P (1 February 2013). "Parvovirus diversity and DNA damage responses". Cold Spring Harb Perspect Biol. 5 (2) a012989. doi:10.1101/cshperspect.a012989. PMC 3552509. PMID 23293137.
  6. ^ a b Qiu J, Söderlund-Venermo M, Young NS (January 2017). "Human Parvoviruses". Clin Microbiol Rev. 30 (1): 43–113. doi:10.1128/CMR.00040-16. PMC 5217800. PMID 27806994.
  7. ^ a b c d e Cotmore SF, Tattersall P (1996). "Parvovirus DNA replication" (PDF). Cold Spring Harbor Monograph Archive. 31: 799–813. doi:10.1101/0.799-813 (inactive 12 July 2025). Archived from the original (PDF) on 17 October 2021. Retrieved 24 January 2021.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
  8. ^ a b c d Kerr, Cotmore & Bloom 2005, p. 175.
  9. ^ a b c Martin DP, Biagini P, Lefeuvre P, Golden M, Roumagnec P, Varsani A (September 2011). "Recombination in eukaryotic single stranded DNA viruses". Viruses. 3 (9): 1699–1738. doi:10.3390/v3091699. PMC 3187698. PMID 21994803.
  10. ^ a b c Kerr, Cotmore & Bloom 2005, p. 173.
  11. ^ Kerr, Cotmore & Bloom 2005, p. 180.
  12. ^ Kerr, Cotmore & Bloom 2005, p. 179.
  13. ^ a b Kerr, Cotmore & Bloom 2005, p. 181.
  14. ^ Kerr, Cotmore & Bloom 2005, p. 171–172, 177, 179.
  15. ^ Kerr, Cotmore & Bloom 2005, p. 182.
  16. ^ Kerr, Cotmore & Bloom 2005, p. 182–184.
  17. ^ a b c Koonin EV, Dolja VV, Krupovic M, Varsani A, Wolf YI, Yutin N, Zerbini M, Kuhn JH (18 October 2019). "Create a megataxonomic framework, filling all principal taxonomic ranks, for ssDNA viruses" (docx). ICTV. Retrieved 24 January 2021.
  18. ^ a b c d Penzes JJ, Soderlund-Venermo M, Canuti M, Eis-Huebinger AM, Hughes J, Cotmore SF. "Re-organize the family Parvoviridae" (docx). ICTV. Retrieved 24 January 2021.
  19. ^ a b "Virus Taxonomy: 2024 Release". International Committee on Taxonomy of Viruses. Retrieved 5 March 2025.
  20. ^ a b c Fonseca EK (February 2018). "Etymologia: Parvovirus". Emerg Infect Dis. 24 (2): 293. doi:10.3201/eid2402.ET2402. PMC 5782889.
  21. ^ Decaro N, Buonavoglia C (24 February 2012). "Canine parvovirus--a review of epidemiological and diagnostic aspects, with emphasis on type 2c". Vet Microbiol. 155 (1): 1–12. doi:10.1016/j.vetmic.2011.09.007. PMC 7173204. PMID 21962408.
  22. ^ Cotmore SF, McKenna MA, Chiorini JA, Gatherer D, Mukha DV, Pintel DJ, Qiu J, Soderland-Venermo M, Tattersall P, Tijssen P. "Rationalization and extension of the taxonomy of the family Parvoviridae" (PDF). ICTV. Retrieved 24 January 2021.
  23. ^ Parrish CR (March 1995). "Pathogenesis of feline panleukopenia virus and canine parvovirus". Baillière's Clin Haematol. 8 (1): 57–71. doi:10.1016/s0950-3536(05)80232-x. PMC 7134857. PMID 7663051.
  24. ^ "Feline panleukopenia". American Veterinary Medical Association. Retrieved 24 January 2021.
  25. ^ Mészáros I, Olasz F, Cságola A, Tijssen P, Zádori Z (20 December 2017). "Biology of Porcine Parvovirus (Ungulate parvovirus 1)". Viruses. 9 (12): 393. doi:10.3390/v9120393. PMC 5744167. PMID 29261104.
  26. ^ Naso MF, Tomkowicz B, Perry WL, Strohl WR (August 2017). "Adeno-Associated Virus (AAV) as a Vector for Gene Therapy". BioDrugs. 31 (4): 317–334. doi:10.1007/s40259-017-0234-5. PMC 5548848. PMID 28669112.
  27. ^ a b Wang D, Tai PW, Gao G (May 2019). "Adeno-associated virus vector as a platform for gene therapy delivery". Nat Rev Drug Discov. 18 (5): 358–378. doi:10.1038/s41573-019-0012-9. PMC 6927556. PMID 30710128.
  28. ^ Kilham L, Olivier LJ (April 1959). "A latent virus of rats isolated in tissue culture". Virology. 7 (4): 428–437. doi:10.1016/0042-6822(59)90071-6. PMID 13669314.
  29. ^ "Parvovirus". Stanford University. Retrieved 24 January 2021.
  30. ^ a b "ICTV Taxonomy history: Rodent protoparvovirus 1". ICTV. Retrieved 24 January 2021.
  31. ^ Kerr, Cotmore & Bloom 2005, p. 171–185.
  32. ^ a b "ICTV Taxonomy history: Adeno-associated dependoparvovirus A". ICTV. Retrieved 24 January 2021.
  33. ^ a b Heegaard ED, Brown KE (July 2002). "Human parvovirus B19". Clin Microbiol Rev. 15 (3): 485–505. doi:10.1128/cmr.15.3.485-505.2002. PMC 118081. PMID 12097253.
  34. ^ "ICTV Taxonomy history: Parvoviridae". ICTV. Retrieved 24 January 2021.
  35. ^ "ICTV Code". ICTV. Retrieved 24 January 2021.

General and cited references

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Parvoviridae

View on Grokipedia
from Grokipedia
Parvoviridae is a family of small, non-enveloped viruses with linear, single-stranded DNA genomes approximately 4–6 kb in length, featuring terminal hairpin structures that facilitate replication. These viruses have icosahedral capsids of T=1 symmetry, measuring 23–28 nm in diameter, composed of 60 copies of a major capsid protein and minor variants with phospholipase A2 activity. The family encompasses pathogens that infect diverse hosts, ranging from vertebrates to invertebrates, and are notable for their resilience, stability in the environment, and dependence on host cell division for propagation. The taxonomy of Parvoviridae, as defined by the International Committee on Taxonomy of Viruses (ICTV), divides the family into three subfamilies: Parvovirinae, Hamaparvovirinae, and Densovirinae. The Parvovirinae subfamily includes 11 genera, such as Protoparvovirus and Dependoparvovirus, comprising 107 species that primarily infect vertebrates including mammals, birds, and reptiles. The Hamaparvovirinae subfamily consists of 6 genera, such as Chaphamaparvovirus, with 98 species infecting diverse hosts including mammals, , and . In contrast, the Densovirinae subfamily consists of 11 genera, like Ambidensovirus and Iteradensovirus, with 38 species targeting invertebrates such as , crustaceans, and echinoderms. This classification reflects host specificity and phylogenetic relationships based on non-structural protein sequences, with ongoing updates incorporating newly discovered viruses through metagenomic approaches. Genomically, parvoviruses encode two main open reading frames: one for non-structural proteins (e.g., NS1/Rep, involved in replication and ) and another for proteins (VP1–VP3). Replication employs a rolling-hairpin mechanism in the host during the , forming double-stranded replicative intermediates and requiring cellular factors or, in some cases, helper viruses like adenoviruses for efficient propagation. The single-stranded genomes package either sense, and their high and recombination rates contribute to diversity and host adaptation. Members of Parvoviridae cause a spectrum of diseases, from subclinical infections to severe conditions; for instance, human erythroparvovirus B19 (Parvovirinae) leads to erythema infectiosum (), transient aplastic crisis, and fetal hydrops. In animals, protoparvovirus 1 () causes lethal and in dogs, while bufavirus and novel human parvoviruses have been linked to . Densoviruses, such as those infecting , pose significant threats to . Due to their for proliferating cells, certain parvoviruses, including adeno-associated virus (a dependoparvovirus), are harnessed as , and others show promise as oncolytic agents against tumors.

Taxonomy

Classification Hierarchy

The family Parvoviridae occupies a specific position in the International Committee on Taxonomy of Viruses (ICTV) hierarchy, reflecting its characteristic single-stranded DNA (ssDNA) genome and replication strategy. It is placed in the realm Monodnaviria, which groups all viruses encoding HUH superfamily endonucleases that initiate rolling-circle replication of ssDNA genomes, distinguishing them from double-stranded DNA viruses in other realms. Within Monodnaviria, Parvoviridae belongs to the kingdom Shotokuvirae, defined by ssDNA viruses that infect eukaryotic hosts and feature a replication initiator protein (Rep) with an N-terminal HUH endonuclease domain, enabling autonomous replication without reliance on host polymerases for the initial strand displacement. This kingdom separates eukaryotic ssDNA viruses from those infecting prokaryotes in the sister kingdom Trapavirae. The phylum Cossaviricota further refines this to viruses with circular or linear ssDNA genomes undergoing rolling-circle replication, emphasizing the conserved Rep protein motifs that cleave and ligate DNA for genome amplification. The class Quintoviricetes encompasses ssDNA viruses with icosahedral capsids and a major capsid protein sharing structural homology, highlighting the evolutionary conservation of the T=1 symmetry in parvoviral virions. Parvoviridae is the sole family in the order Piccovirales, which unites small, non-enveloped ssDNA viruses (18–26 nm in diameter) that lack an and rely on host nuclear machinery for replication, a trait setting them apart from larger or enveloped DNA viruses. As of the 2025 ICTV release, Parvoviridae comprises 28 genera and 298 . Significant updates to the Parvoviridae taxonomy occurred between and , primarily through a 2020 reorganization that formalized its placement in the realm and introduced structural refinements to subfamilial divisions based on host range and genomic features. Subsequent annual ICTV ratifications from 2021 to 2024 focused on species expansions, incorporating newly discovered parvoviruses from diverse hosts without altering the higher-level hierarchy. The 2025 ratification added 55 new species (29 in Parvovirinae and 26 in Densovirinae), primarily identified through metagenomic approaches, bringing the total to 298 species as of July 2025, with no further changes reported by November 2025.

Subfamilies and Genera

The family Parvoviridae is divided into three subfamilies based on phylogenetic relationships and host associations, as ratified by the International Committee on Taxonomy of Viruses (ICTV) in 2020: Parvovirinae, Hamaparvovirinae, and Densovirinae. This classification reflects a shift from host-based canonical approaches to one emphasizing genetic and structural features, accommodating the family's diverse single-stranded DNA viruses. The subfamily Parvovirinae primarily infects vertebrate hosts, including mammals, birds, and reptiles, and encompasses eleven genera: Amdoparvovirus, Artiparvovirus, Aveparvovirus, Bocaparvovirus, Copiparvovirus, Dependoparvovirus, Erythroparvovirus, Loriparvovirus, Protoparvovirus, Tetraparvovirus, and one additional genus established post-2020. Notable examples include the genus Protoparvovirus, which contains canine parvovirus (CPV), a significant pathogen in dogs first identified in 1978, and human parvovirus B19; Dependoparvovirus, featuring adeno-associated viruses (AAVs) that require helper viruses for replication and are widely used in gene therapy; and Amdoparvovirus, represented by Aleutian mink disease virus (AMDV), which causes chronic infections in mustelids. These genera highlight the subfamily's broad vertebrate tropism, with many members identified through classical virology and emerging metagenomic surveys. The subfamily Hamaparvovirinae, newly established in 2020 to resolve ambiguities in ambisense organization, includes viruses that infect both vertebrates and , with a focus on mammalian and aquatic hosts in five genera: Brevihamaparvovirus, Chaphamaparvovirus, Hepanhamaparvovirus, Ichthamaparvovirus, and Penstylhamaparvovirus. Key examples are the genus Chaphamaparvovirus, encompassing rodent chapparvoviruses like mouse kidney parvovirus discovered via in 2012, which have expanded the known diversity of mammalian parvoviruses; and Ichthamaparvovirus, featuring parvovirus, identified in fish and reflecting cross-species potential. This subfamily's genera often stem from recent metagenomic discoveries, underscoring ongoing taxonomic expansions as of 2025. In contrast, the subfamily Densovirinae is restricted to invertebrate hosts, particularly arthropods such as and crustaceans, as well as echinoderms, and comprises eleven genera, including Ambidensovirus (with subgroups like aquambidensoviruses and protoambidensoviruses), Brevidensovirus, Hepandensovirus, Iteradensovirus, Blattambidensovirus, Penstyldensovirus, Miniambidensovirus, Scindoambidensovirus, and others. A representative genus is Iteradensovirus, which includes insect-specific viruses such as densovirus, a of silkworms that has been studied since the 1970s for its economic impact on . Metagenomic efforts have revealed additional diversity within this subfamily, including novel densoviruses in , contributing to proposals for new genera and the 2025 addition of 26 species. Overall, these subfamilial divisions emphasize Parvoviridae's ecological partitioning, with Parvovirinae and Hamaparvovirinae dominating vertebrate viromes and Densovirinae confined to .

Physical Properties

Genome Organization

The genomes of viruses in the family Parvoviridae are linear and single-stranded DNA (ssDNA), typically ranging from 4 to 6 kilobases (kb) in length. These compact genomes are monopartite and encode all necessary viral proteins within this limited space, reflecting the family's evolutionary adaptation to efficient replication in diverse hosts. Depending on the subfamily, parvoviruses package either predominantly one polarity of the ssDNA strand or both polarities. In the subfamily Parvovirinae, which infects vertebrates, virions primarily encapsidate negative-sense strands (approximately 85% of the population), while the positive-sense strand serves as the template for transcription. In contrast, members of the subfamily Densovirinae, which primarily infect invertebrates, package both positive- and negative-sense strands in roughly equal proportions, enabling ambisense gene expression from either strand. This variation in strand packaging influences the initial steps of infection and replication but does not alter the overall linear ssDNA architecture. At both termini, the genome features short, imperfect palindromic sequences that fold into hairpin structures, typically 100–250 nucleotides (nt) in length, such as the 115–116 nt at the 3' end and 200–242 nt at the 5' end observed in protoparvoviruses like the minute virus of mice. These terminal hairpins, which constitute about 5–10% of the genome, are essential for priming DNA synthesis during the virus's unique rolling-hairpin replication mechanism, where the hairpin resolves and transfers to initiate iterative displacement synthesis. The hairpins exhibit genus-specific variations in sequence and complexity, with some featuring Y- or T-shaped configurations that further stabilize the ends and regulate replication initiation. The coding region is organized into two major open reading frames (ORFs): the non-structural (NS or Rep) genes located toward the 5' end and the structural (VP) genes toward the 3' end. The NS1 (or Rep1) protein, encoded by the major NS ORF, functions as the primary replication initiator with and endonuclease activities, while smaller NS2 (or Rep2/Rep3) proteins arise via and support nuclear localization and replication complex assembly. The VP ORF overlaps partially with the NS region and encodes the proteins VP1, VP2, and VP3 through a combination of and post-translational cleavage; VP1 includes a unique N-terminal domain for endosomal escape, while VP2 and VP3 form the bulk of the icosahedral . This arrangement exemplifies the family's reliance on overlapping reading frames to maximize coding capacity within the small . Alternative splicing of pre-mRNAs transcribed from the single-stranded (after conversion to double-stranded form) generates multiple mature mRNAs from a limited number of promoters, typically two per genome (e.g., P4 and P40 in protoparvoviruses). This strategy produces the diverse NS and VP isoforms efficiently, with splicing sites conserved across genera to ensure balanced expression of replication and structural proteins. Such compact organization minimizes redundancy and allows rapid adaptation, though it constrains the virus's genetic flexibility. Parvovirus genomes exhibit a relatively high for DNA viruses, approximately 10−410^{-4} substitutions per site per year, driven by error-prone host DNA polymerases during S-phase replication and the inherent instability of ssDNA. This rate, comparable to some viruses, facilitates antigenic variation and host adaptation but also contributes to the emergence of pathogenic strains, as documented in seminal studies on protoparvoviruses.

Virion Structure

The Parvoviridae virion is a non-enveloped, icosahedral particle exhibiting T=1 symmetry and measuring 23–28 nm in . It consists of a protein enclosing the single-stranded DNA , with no associated , carbohydrates, or histones. The is assembled from 60 copies of (VP) monomers, primarily derived from overlapping reading frames that produce two or three structural variants depending on the . The capsid proteins include VP1, the largest isoform with a unique N-terminal extension containing a phospholipase A2 (PLA2) domain essential for endosomal escape during infection; VP2, the predominant structural component that forms the bulk of the capsid scaffold; and VP3, a minor truncated form of VP2 generated by proteolytic cleavage. Ratios vary by subfamily: in dependoparvoviruses such as adeno-associated virus, VP1:VP2:VP3 is approximately 1:1:10 (~5:5:50 copies); in protoparvoviruses, VP1:VP2/VP3 is approximately 1:10 (~5:55 copies), with VP3 derived from VP2 cleavage. The shared C-terminal regions of these proteins form the core β-barrel structure, while the VP1-specific N-terminus remains largely internal until activation. Surface topography of the features depressions at the icosahedral 2-fold and 3-fold axes, protrusions surrounding the 3-fold vertices, and cylindrical channels at the 5-fold axes that function as portals for packaging. These 5-fold channels penetrate the shell, facilitating the insertion of the linear ssDNA during assembly. The protrusions at 5-fold vertices contribute to the portal's role in encapsidation. The is packaged within the via these 5-fold portals during virion maturation. Parvoviridae virions exhibit remarkable physicochemical stability, resisting low pH (down to 3 for 60 minutes), heat up to 60°C for 60 minutes, and organic solvents such as and . This robustness aids environmental persistence and transmission. High-resolution insights into capsid architecture have been provided by cryo-electron microscopy (cryo-EM) and , revealing atomic details of subunit interactions and assembly interfaces. For instance, 2022 cryo-EM studies of Aleutian mink disease virus and human parvovirus 4 capsids at resolutions of 2.37 Å and 3.12 Å, respectively, highlighted conserved motifs in assembly and evolutionary adaptations in surface loops, as discussed in a 2025 review. These techniques have elucidated dynamic conformational changes during capsid formation, emphasizing the role of inter-monomer contacts in stabilizing the T=1 lattice.

Replication

Life Cycle

Parvoviruses of the family Parvoviridae initiate their replication cycle through into host cells. For instance, some parvoviruses, such as (AAV), utilize the for attachment and entry. Following binding, the virion is internalized via clathrin-dependent endocytosis. Uncoating occurs within the , facilitated by the (PLA2) activity in the unique N-terminal region of the minor protein VP1. This enzymatic function disrupts the endosomal membrane, promoting escape of the viral into the cytoplasm. The single-stranded DNA is then released from the partially disassembled . The viral genome translocates to the nucleus, where the terminal structures self-prime to form a double-stranded replicative intermediate. Nuclear import is mediated by nuclear localization signals on the capsid proteins, allowing the genome to enter through nuclear pores or via transient disruption of the in some cases. Replication proceeds via a rolling- mechanism, initiated by the viral non-structural protein NS1, which introduces a nick at the terminal resolution site. This process displaces one strand while synthesizing the complementary strand using host , generating linear concatemers that are resolved into monomeric genomes by transfer. Replication is dependent on host cell machinery and typically occurs during the of the for autonomous parvoviruses. Transcription of viral genes relies on host RNA polymerase II, which recognizes the double-stranded replicative form to produce pre-mRNAs from bidirectional promoters. These transcripts are alternatively spliced and polyadenylated to encode non-structural proteins like NS1 and structural capsid proteins VP1 and VP2. Capsid assembly takes place in the nucleus, where VP1 and VP2 proteins self-assemble into icosahedral particles, encapsidating newly replicated single-stranded DNA genomes. Packaging is directed by the terminal hairpins, ensuring selective inclusion of mature genomes. Progeny virions are released primarily through host cell lysis, though dependoviruses like AAV may require helper viruses for egress and maturation. In permissive cells, the entire replication cycle typically completes within 24–48 hours.

Host Interactions

Parvoviridae viruses initiate infection by binding to specific host cell surface receptors, which are critical determinants of tissue and host range. Many members utilize glycan-based receptors for attachment, such as for porcine parvovirus or globoside for , a P-antigen predominantly expressed on erythroid cells. In contrast, adeno-associated viruses (AAVs) in the Dependoparvovirus often employ proteoglycans as primary receptors, with subsequent engagement of protein coreceptors like AAVR (KIAA0319L) or to facilitate entry. These receptor interactions not only dictate cellular entry but also influence viral ; for example, tissue-specific expression of the governs the host range of carnivore parvoviruses, such as , which evolved to bind feline versus canine variants through adaptations. Dependoparvoviruses exhibit a distinctive reliance on helper viruses to overcome limitations in their replication cycle, highlighting a complex interplay with co-infecting agents. AAVs require adenovirus, herpesvirus, or certain bocaviruses to supply factors, including E1A, E4, and VA RNA from adenoviruses, which activate viral promoters and alleviate translational repression. This dependence allows AAVs to persist latently in host cells without causing , integrating their into host DNA in the absence of helpers, but it restricts autonomous replication and shapes dynamics in multi-viral environments. Autonomous parvoviruses, however, replicate independently while still exploiting host machinery. Parvoviral replication depends on host DNA polymerases to synthesize second-strand DNA from the incoming single-stranded . To optimize replication, Parvoviridae manipulate host cell cycle progression, primarily by inducing G2/M phase arrest through activation of the DNA damage response (DDR). Viral replication intermediates, particularly from NS1-induced nicking of the genome, trigger DDR kinases like ATM and ATR, leading to phosphorylation of checkpoint proteins such as Chk1 and Chk2, which halt mitosis and enrich S-phase conditions favorable for viral DNA synthesis. This arrest is evident in infections by human parvovirus B19 and minute virus of mice, where it enhances progeny production without requiring p53-dependent pathways. Such manipulation underscores the viruses' exploitation of host regulatory networks. Parvoviridae evade host immune responses through mechanisms involving both nonstructural proteins and capsid features. The NS1 protein modulates innate immunity by altering inflammatory signaling, such as inhibiting NF-κB activation in parvovirus B19-infected cells, while also inducing apoptosis via DNA damage and caspase activation to limit immune cell persistence. This dual role—dampening cytokine production yet promoting cell death—helps sustain infection. Capsids contribute to evasion by structural adaptations; antigenic drift in surface loops allows escape from neutralizing antibodies, as seen in canine parvovirus variants that alter epitopes to persist in immune hosts. Additionally, circulating B19 virions can be coated with complement components, potentially shielding them from antibody recognition. Metagenomic surveys in 2025 have expanded understanding of Parvoviridae diversity in natural hosts. For example, analysis of viromes from herbivorous wildlife on the Qinghai-Tibet Plateau identified diverse parvoviruses, including lineages in the Hamaparvovirinae subfamily infecting vertebrates, and Densovirinae potentially acquired through diet from . These findings highlight ecological interactions, potential , and the role of arthropods in parvovirus dynamics.

Evolution

Phylogenetic Origins

The Parvoviridae family exhibits ancient origins, with phylogenetic analyses of the replication-associated NS1 indicating that the split between invertebrate-infecting (Densovirinae) and vertebrate-infecting (Parvovirinae and Hamaparvovirinae) lineages occurred more than 500 million years ago, predating the divergence of from . This deep evolutionary history is supported by endogenous parvoviral elements (EPVs) integrated into vertebrate genomes, which provide fossil-calibrated minimum ages for viral clades, such as greater than 100 million years ago for Amdoparvovirus and over 80 million years ago for broader Parvovirinae sublineages. Phylogenetic reconstructions, primarily based on the NS1 protein sequences with supplementary analysis of the capsid VP genes, position Densovirinae as the basal subfamily relative to vertebrate parvoviruses, reflecting their adaptation to arthropod hosts early in the family's evolution. These trees demonstrate clear separation of subfamilies, with NS1 sharing detectable homology across Parvovirinae genera but greater divergence from Densovirinae, underscoring the family's monophyletic structure despite host-specific radiations. Within Parvovirinae, host co-speciation with s is evident from time-calibrated phylogenies that align viral diversification with major vertebrate radiations, including vicariance events in mammals like and marsupials for Protoparvovirus clades. Fossil-calibrated analyses using EPVs confirm long-term co-circulation of multiple genera alongside vertebrate hosts, with adaptations to ecological niches driving over tens of millions of years. Cross-species transmission events punctuate this co-evolutionary pattern, as illustrated by bufavirus (BuV), a Protoparvovirus initially detected in fecal samples and later identified in such as rats, , and nonhuman , suggesting zoonotic jumps from reservoirs to humans. Recent 2025 analyses of endemic and emerging strains, including feline panleukopenia virus (FPV)-like viruses in wild reservoirs, reveal slower evolutionary rates—approximately 25% of those observed in domestic host-adapted strains like (CPV)—highlighting constrained diversification in natural populations compared to rapid adaptation in emerging pandemics.

Genetic Mechanisms

Parvoviridae exhibit a high mutation rate of approximately 10^{-4} substitutions per base, driven by their error-prone replication mechanism that lacks proofreading exonuclease activity during the synthesis of their single-stranded DNA genomes using host polymerases. This elevated rate, comparable to that of some RNA viruses despite their DNA nature, arises from the rolling-hairpin replication process. Consequently, this facilitates rapid genetic diversification, enabling adaptation to host immune responses and environmental pressures within infected tissues. Recombination events are prominent hotspots within the VP genes, particularly at the VP1/VP2 boundary, promoting antigenic variation as seen in the emergence of type 2 (CPV-2) variants from feline panleukopenia virus (FPV) ancestors. These intra- and inter-genotypic recombinations shuffle protein sequences, altering epitopes to evade neutralizing antibodies while maintaining structural integrity for host cell entry, as evidenced by CPV-2a, -2b, and -2c strains that arose through such mechanisms in the late 1970s and 1980s. This process enhances viral fitness by combining beneficial mutations from diverse parental strains, contributing to the global spread of antigenic variants. Selection pressures act distinctly on viral proteins, with positive selection favoring immune escape mutations in the (VP1/VP2) to alter receptor binding and recognition sites, while negative selection dominates in the non-structural protein 1 (NS1) to preserve essential replicative functions. These dynamics underscore the evolutionary constraints on multifunctional proteins like NS1, which coordinates replication and immune modulation. Within hosts, Parvoviridae populations maintain quasispecies dynamics, characterized by a swarm of closely related variants arising from ongoing mutations and minority subpopulations that confer adaptability to heterogeneous microenvironments such as varying immune pressures or tissue types. This intra-host diversity, resembling that of RNA viruses, allows rapid selection of fitter clones during acute infection, as observed in CPV-2 where VP2 heterogeneity exceeds 1% at the level in individual animals. Recent 2025 analyses of wild-type sequences reveal that CPV evolves approximately four times faster than FPV-like strains in dogs, with substitution rates around 2 × 10^{-4} sites^{-1} year^{-1} for CPV versus 5 × 10^{-5} for FPV, directly linking this accelerated pace to the virus's pandemic emergence and sustained circulation. This disparity highlights host-specific evolutionary acceleration in CPV, driven by stronger immune selection in canine populations compared to the more stable feline niche.

Pathogenesis

Diseases in Animals

Parvoviridae viruses cause a range of significant diseases in non-human animals, particularly affecting companion animals, , and species, with high morbidity and mortality in susceptible populations. In dogs, (CPV), a protoparvovirus, induces acute hemorrhagic and , leading to severe vomiting, bloody , , and , especially in puppies under six months old, with mortality rates exceeding 90% without supportive care. Similarly, feline panleukopenia virus (FPV), closely related to CPV, causes panleukopenia, , and in cats, manifesting as fever, anorexia, and profound , with neonates at risk for or . In mustelids such as , amdoparvovirus (AMDV) triggers Aleutian mink disease, characterized by hyperplasia, immune complex deposition, hypergammaglobulinemia, and chronic , resulting in progressive , , and reduced . In insects, densoviruses from the subfamily Densovirinae infect arthropods, including economically important species; for instance, stylirostris densovirus (PstDNV), also known as infectious hypodermal and hematopoietic virus (IHHNV), causes runt-deformity in , leading to stunted growth, deformities, and high mortality in juvenile stylirostris, though it often results in chronic infections in other penaeid species like vannamei. In bees, densoviruses have been detected in viromes, with potential pathogenicity in that may include symptoms such as paralysis, though their specific role in health and colony decline requires further investigation and contributes to ongoing research on threats to health. Transmission of these parvoviruses primarily occurs via the fecal-oral route, direct contact with infected bodily fluids, or fomites, with possible in some cases, such as transplacental infection in mammals or transovarial in . Incubation periods typically range from 3 to 7 days for acute enteric forms like CPV and FPV, though AMDV may take weeks to months to manifest clinically. relies on molecular methods such as PCR for viral DNA detection in feces, tissues, or blood, alongside serological assays like for antibodies, and in some cases, or electron microscopy. These diseases impose substantial economic burdens on veterinary and agricultural sectors; CPV and FPV outbreaks in populations drive high treatment and costs, while AMDV leads to significant losses in the global mink fur industry through and reduced pelt quality. In aquaculture, IHHNV contributes to multimillion-dollar impacts via reduced yields and restrictions. Recent metagenomic studies in 2025 have uncovered novel parvovirus strains in domestic pigeons, including previously unknown variants detected in racing flocks, potentially linked to respiratory and enteric issues, and in herbivorous such as yaks and gazelles on the Qinghai-Tibet Plateau, revealing 32 diverse parvoviruses that highlight expanding host ranges and zoonotic risks. Host cell receptor interactions, such as the for CPV and FPV in carnivores, further dictate tissue specificity and disease severity.

Diseases in Humans

Parvovirus B19 is the primary pathogenic member of the Parvoviridae family that infects humans, causing a range of clinical manifestations primarily through its replication in erythroid progenitor cells. In children, the most common presentation is erythema infectiosum, also known as , characterized by a distinctive "slapped cheek" rash and lacy exanthem on the trunk and limbs following a mild prodromal illness. In adults, particularly women, acute arthropathy affecting the hands, wrists, knees, and ankles can predominate, often resolving within weeks but occasionally persisting longer. In individuals with underlying hemolytic anemias such as , B19 infection can trigger severe aplastic crises due to abrupt cessation of production, leading to profound that may require transfusion. During pregnancy, transplacental transmission can result in fetal hydrops and nonimmune , with risks of or fetal death in up to 10% of cases when infection occurs in the first or second trimester. The of B19 infection centers on its strict for human erythroid progenitor cells in the , mediated by binding to the P antigen (globoside), a glycosphingolipid receptor expressed abundantly on these cells. Viral entry and replication induce arrest at the , , and of infected progenitors, resulting in transient bone marrow aplasia and a temporary drop in count, typically resolving as the clears the virus. This erythroid-specific pathology explains the in vulnerable hosts but spares mature erythrocytes, which lack sufficient receptors. Epidemiologically, B19 infection is ubiquitous worldwide, with seroprevalence reaching 50-80% in adults, indicating lifelong immunity post-infection, and no known animal reservoir for the virus. Transmission occurs primarily via respiratory droplets, with outbreaks cycling every 3-4 years and seasonal peaks typically in late winter to early summer, particularly in temperate regions. In contrast, emerging protoparvoviruses like bufavirus and cutavirus, discovered through metagenomic surveys in the , may have zoonotic potential, as bufavirus strains have been identified in and nonhuman . Bufavirus, first detected in human fecal samples from patients with acute in 2013, has been associated with in children and adults, though its causative role remains under investigation due to frequent co-detection with other enteric pathogens. Cutavirus, identified in 2016 via in stool and skin samples, shows links to cutaneous lesions, including detection in biopsies from and large-plaque parapsoriasis, premalignant conditions that may progress to . Recent studies up to 2025 have utilized NS1 gene to trace B19 strain during outbreaks, revealing clustering of genotype 1a variants in recent epidemics and informing for emerging parvovirus diversity.

Applications

Gene Therapy

Adeno-associated virus (AAV), a member of the Dependoparvovirus genus within the family, serves as a primary vector for due to its non-pathogenic nature in humans and ability to establish long-term expression. Unlike integrating vectors, recombinant AAV (rAAV) genomes predominantly persist as episomes in the nucleus of non-dividing cells, minimizing risks of while enabling sustained therapeutic protein production over years. This episomal maintenance, combined with broad tissue across serotypes, has positioned AAV as a cornerstone for delivering functional genes to treat monogenic disorders. Clinical applications of AAV vectors have advanced significantly, with Luxturna (voretigene neparvovec-rzyl), an AAV2-based therapy, receiving FDA approval in December 2017 for treating biallelic mutation-associated retinal by subretinal delivery of a functional to restore vision. Approved AAV therapies for hemophilia B include etranacogene dezaparvovec (AAV5-based, approved November 2022), which showed sustained expression over five years in the HOPE-B trial, reducing bleeding episodes, and fidanacogene elaparvovec (Beqvez, AAV5-based, approved April 2024 but discontinued by manufacturer in February 2025). For (DMD), delandistrogene moxeparvovec (Elevidys, AAVrh74-based) was approved in June 2023 for ambulatory patients aged 4 and older with confirmed DMD mutations (excluding exons 8 and/or 9 deletions); the approval was expanded in June 2024 but revised in November 2025 to limit use to ambulatory patients following reports of fatal adverse events in non-ambulatory individuals, with added safety warnings. The confirmatory EMBARK phase 3 trial (NCT05096221) did not meet its primary endpoint at 52 weeks but demonstrated improvements in secondary motor function measures, such as the North Star Ambulatory Assessment, in ambulatory DMD patients. These developments highlight AAV's potential to address unmet needs in rare diseases through one-time administration. Vector design leverages AAV's genomic structure, utilizing inverted terminal repeats (ITRs) derived from the wild-type genome to flank the therapeutic transgene for efficient packaging into the capsid, which can hold up to 4.7 kb of DNA. Capsid engineering enhances specificity, with rational and directed evolution techniques generating variants like AAV9 or AAVphp.B that improve tissue targeting to the central nervous system, liver, or muscle while evading immune clearance. AAV vectors offer advantages such as low immunogenicity—eliciting minimal innate immune activation—and scalable production yielding high titers exceeding 10^13 vector genomes per liter. However, challenges persist, including pre-existing neutralizing antibodies in up to 70% of the population that can reduce transduction efficiency and trigger inflammatory responses. Production of clinical-grade AAV relies on helper virus-free systems, typically involving triple plasmid transfection of HEK293 cells with plasmids encoding the AAV rep/cap genes, adenoviral helper functions, and the ITR-flanked transgene. This adherent or suspension culture method in HEK293 cells—chosen for their endogenous expression of adenovirus E1 proteins—enables high-yield, contamination-free vector generation without requiring wild-type helper viruses like adenovirus. Recent optimizations, including continuous harvest from bioreactor cultures, have further increased scalability to support widespread therapeutic use.

Vaccine Development

Vaccine development for pathogenic members of the Parvoviridae family has primarily focused on veterinary applications, with modified-live vaccines against canine parvovirus (CPV) and feline panleukopenia virus (FPV) introduced shortly after CPV's emergence in 1978. These vaccines, derived from attenuated strains of CPV-2 or FPV, have been routinely administered to dogs and cats, significantly reducing disease incidence by stimulating humoral immunity through capsid protein antigens. Current modified-live CPV and FPV provide high rates, typically 90-95% in vaccinated populations when administered according to protocols that account for maternal interference. However, maternally derived antibodies in puppies and kittens can neutralize the , leading to failures if dosing occurs too early, typically requiring initial at 6-8 weeks followed by boosters. Antigenic drift in CPV, driven by mutations in the VP2 protein (e.g., Asp426Glu), has resulted in variants like CPV-2a, 2b, and 2c, necessitating periodic updates to maintain cross-protection, as early FPV-based formulations showed variable efficacy against emerging CPV strains. For human , no licensed exists as of November 2025, though recombinant candidates based on and VP2 proteins, often as virus-like particles (VLPs), have advanced to early clinical evaluation. These VLPs mimic the viral structure to elicit neutralizing antibodies without replication risk, with phase I trials targeting high-risk groups such as pregnant women and immunocompromised individuals demonstrating and safety in preclinical and initial human studies. In , (RNAi)-based strategies offer preventive control against densoviruses like infectious hypodermal and hematopoietic virus (IHHNV) in , where double-stranded RNA targeting viral genes silences replication and reduces mortality. These non-vaccine approaches, delivered via feed or immersion, have shown promise in field trials by selectively inhibiting densovirus propagation without broad-spectrum antibiotics. Recent advances include studies on updated CPV incorporating variant-specific antigens to counter ongoing antigenic drift, with attenuated live strains maintaining efficacy against CPV-2c while addressing maternal challenges through optimized dosing. These developments emphasize the need for of circulating strains to ensure relevance in veterinary practice.

History

Discovery

The discovery of viruses in the Parvoviridae family began in the mid-20th century with isolations from animal sources, facilitated by advances in cell culture and electron microscopy. The first densovirus, infecting the wax moth Galleria mellonella, was isolated in 1964, marking an early recognition of parvoviruses in invertebrates. The adeno-associated virus (AAV), now classified in the genus Dependoparvovirus, was first identified in 1965 as a frequent contaminant in adenovirus preparations during electron microscopy examinations by researchers at the University of Pittsburgh. These small, 20-25 nm particles were observed in human and monkey cell cultures and later confirmed to require adenovirus for replication. Concurrently, the autonomous protoparvovirus known as the minute virus of mice (MVM) was isolated in 1966 by L.V. Crawford from mouse embryo fibroblast cultures contaminated with adenovirus stocks, marking one of the earliest characterizations of a replicating parvovirus in mammals. Bovine parvovirus (BPV), another bocaparvovirus, was isolated even earlier in 1961 from the diarrheic feces of calves by F.R. Abinanti and N.W. Warfield, initially termed the Hemadsorption Enteric agent (HADEN) due to its hemagglutination properties observed in cell cultures. The identification of a human parvovirus came in 1975 through serendipitous electron microscopy screening of blood donor sera for hepatitis B surface antigen by Cossart and colleagues at the Central Public Health Laboratory in . Parvovirus-like particles, approximately 23 nm in diameter, were detected in serum sample B19 from a panel of 192 donations, leading to the virus's naming based on this panel code. This discovery, published in , represented the first documented human member of the family and highlighted the utility of electron microscopy in detecting non-culturable viruses in clinical samples. Cossart's work built on earlier and spurred investigations into parvovirus-associated diseases, such as erythema infectiosum (). Classification milestones followed rapidly, with the International Committee on Taxonomy of Viruses (ICTV) formally establishing the Parvoviridae family in 1975 to encompass these small, single-stranded DNA viruses, initially as a single genus Parvovirus. Key contributions from researchers like Gerhard Siegl, who reviewed the biology and pathogenicity of autonomous parvoviruses in the 1980s, helped delineate their replication strategies and host ranges. In 1993, the family was reorganized into two subfamilies—Parvovirinae for vertebrate-infecting viruses and Densovirinae for invertebrate hosts—reflecting host specificity. Further refinements occurred in 2014 with the addition of new genera like Tetraparvovirus, driven by metagenomic sequencing of novel viruses. In 2020, informed by metagenomics, the taxonomy was expanded to include a third subfamily, Hamaparvovirinae, accommodating viruses with ambiguous host tropisms discovered in environmental and animal samples, thus broadening the family's recognized diversity.

Etymology

The name Parvoviridae is derived from the Latin word parvus, meaning "small," which reflects the characteristically small size of the virions in this family, measuring less than 30 nm in . Within the family, the Parvovirinae encompasses viruses that primarily infect vertebrates and retains the root from the family name, emphasizing their small, vertebrate-associated parvoviruses. In contrast, the Densovirinae derives from "densovirus," coined for the dense observed in early isolates, with "denso" stemming from the Latin densus, meaning "thick" or "compact." Genus names within Parvoviridae follow similar descriptive conventions; for instance, Protoparvovirus incorporates the prefix "proto-," indicating the primitive or earliest-discovered parvoviruses in the subfamily Parvovirinae. Likewise, Dependoparvovirus highlights the biological dependency of its members on helper viruses, such as adenoviruses, for productive replication in host cells. Historically, naming in Parvoviridae has evolved under the rules of the International Committee on Taxonomy of Viruses (ICTV), transitioning from ad hoc designations based on host or disease to systematic that aligns with phylogenetic relationships. For example, variants of , initially labeled as CPV-2 and its subtypes, are now formally classified as distinct species within to reflect genetic and antigenic differences.

References

  1. https://ictv.global/report/chapter/parvoviridae/parvoviridae
  2. https://www.ncbi.nlm.nih.gov/books/NBK7715/
  3. https://pubmed.ncbi.nlm.nih.gov/40711809/
  4. https://pubmed.ncbi.nlm.nih.gov/32533329/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7173204/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4013247/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6537627/
  8. https://link.springer.com/article/10.1007/s00705-020-04632-4
  9. https://ictv.global/virus-properties?page=4
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC12451622/
  11. https://doi.org/10.1007/s00705-020-04632-4
  12. https://ictv.global/report_9th/ssDNA/Parvoviridae
  13. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/parvoviridae
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3552509/
  15. https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.001212
  16. https://viralzone.expasy.org/103
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC12298888/
  18. https://www.nature.com/articles/s41467-023-38875-x
  19. https://www.nature.com/articles/srep35759
  20. https://pubmed.ncbi.nlm.nih.gov/12552010/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC10373561/
  22. https://journals.asm.org/doi/pdf/10.1128/jvi.00161-23
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4524367/
  24. https://www.sciencedirect.com/topics/immunology-and-microbiology/parvoviridae
  25. https://journals.asm.org/doi/10.1128/jvi.03157-14
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3126206/
  27. https://www.karger.com/Article/Pdf/149884
  28. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/parvoviridae
  29. https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2025.1559461/full
  30. https://www.researchgate.net/publication/364513033_Capsid_Structure_of_Aleutian_Mink_Disease_Virus_and_Human_Parvovirus_4_New_Faces_in_the_Parvovirus_Family_Portrait
  31. https://journals.asm.org/doi/10.1128/jvi.00161-23
  32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470565/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4470565/
  34. https://www.sciencedirect.com/science/article/pii/S1534580701000314
  35. https://onlinelibrary.wiley.com/doi/10.1111/mmi.14974
  36. https://www.nature.com/articles/263106a0
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4149944/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3185660/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6475792/
  40. https://pubmed.ncbi.nlm.nih.gov/12941411/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2863798/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC7354565/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC7474932/
  44. https://pubmed.ncbi.nlm.nih.gov/28659483/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3457271/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4242421/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC2951379/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC2519586/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6468957/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC11538491/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC12355741/
  52. https://journals.asm.org/doi/10.1128/spectrum.04570-22
  53. https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001867
  54. https://virologyj.biomedcentral.com/articles/10.1186/s12985-019-1278-6
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC4480391/
  56. https://www.biorxiv.org/content/10.1101/2025.07.14.664739v1
  57. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0111779
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC9781796/
  59. https://www.researchgate.net/publication/370871243_Viral_Capsid_Antibody_and_Receptor_Interactions_Experimental_Analysis_of_the_Antibody_Escape_Evolution_of_Canine_Parvovirus
  60. https://pubmed.ncbi.nlm.nih.gov/16822535/
  61. https://www.sciencedirect.com/science/article/pii/S0042682206003928
  62. https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-025-05019-w
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8542416/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC2953158/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC11019937/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC8360955/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC3550757/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC11783907/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC118081/
  70. https://ijponline.biomedcentral.com/articles/10.1186/s13052-024-01831-6
  71. https://pubmed.ncbi.nlm.nih.gov/8211117/
  72. https://www.sciencedirect.com/science/article/pii/S2949688823000072
  73. https://www.nejm.org/doi/full/10.1056/NEJM199501123320216
  74. https://pubmed.ncbi.nlm.nih.gov/25283854/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC12030994/
  76. https://wwwnc.cdc.gov/eid/article/21/7/14-1969_article
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC4036783/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC5324802/
  79. https://link.springer.com/article/10.1007/s00705-025-06228-2
  80. https://www.addgene.org/guides/aav/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC5548848/
  82. https://www.nature.com/articles/s41392-024-01780-w
  83. https://www.fda.gov/media/109906/download
  84. https://www.fda.gov/news-events/press-announcements/fda-approves-new-safety-warning-and-revised-indication-limits-use-elevidys-following-reports-fatal
  85. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-fdas-approval-updated-elevidys-prescribing
  86. https://www.nejm.org/doi/abs/10.1056/NEJMoa2414783
  87. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec
  88. https://www.sciencedirect.com/science/article/pii/S1525001625002734
  89. https://www.sciencedirect.com/science/article/pii/S1525001625002655
  90. https://www.sciencedirect.com/science/article/pii/S0167779922003031
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC10845199/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC4817810/
  93. https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501%2818%2930047-0
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC7113661/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7149312/
  96. https://onlinelibrary.wiley.com/doi/10.1111/j.1439-0450.2005.00868.x
  97. https://pubmed.ncbi.nlm.nih.gov/23561891/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC12390283/
  99. https://www.sciencedirect.com/science/article/pii/S1879437814000138
  100. https://www.researchgate.net/publication/354927788_Effect_of_maternal_antibodies_on_the_immune_response_to_different_canine_parvovirus_vaccines_and_antibody_response_to_selected_vaccines
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC12430823/
  102. https://www.sciencedirect.com/science/article/pii/S0264410X22011045
  103. https://www.researchgate.net/publication/364971683_Recombinant_Virus-like_Particles_of_Human_Parvovirus_B19_with_the_Internal_Location_of_VP1_Unique_Region_Produced_by_Hansenula_polymorpha
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC10612085/
  105. https://www.sciencedirect.com/science/article/abs/pii/S1050464825008022
  106. https://pubs.acs.org/doi/abs/10.1021/acs.jafc.1c00268
  107. https://pubmed.ncbi.nlm.nih.gov/40843250/
  108. https://www.researchgate.net/publication/395170709_Correction_Decoding_canine_parvovirus_biomarkers_for_diagnosis_and_advances_in_vaccine_development_to_address_emerging_challenges
  109. https://pubmed.ncbi.nlm.nih.gov/5945715/
  110. https://www.researchgate.net/publication/330570174_ICTV_Virus_Taxonomy_Profile_Parvoviridae
  111. https://www.etymonline.com/word/parvovirus
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC5782889/
  113. https://link.springer.com/article/10.1007/s00705-013-1914-1
  114. https://www.sciencedirect.com/topics/medicine-and-dentistry/dependoparvovirus
Add your contribution
Related Hubs
User Avatar
No comments yet.